Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the idiopathic pulmonary fibrosis market?

The market for idiopathic pulmonary fibrosis has seen robust growth in the past few years. It is projected to expand from $4.15 billion in 2024 to $4.39 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. Factors contributing to the growth during the historical period include an increase in the aging population, restricted treatment alternatives, heightened disease awareness, and advancements in healthcare infrastructure.

What will be the idiopathic pulmonary fibrosis market size in the future?

Expectations are high for robust expansion in the idiopathic pulmonary fibrosis market over the upcoming years. The market value is slated to reach $5.74 billion by 2029, representing a compound annual growth rate (CAGR) of 7.0%. Factors contributing to this anticipated growth during the forecast period include amplified research and development efforts, a precision medicine approach, a rising incidence of the disease, advances in biomarker development, as well as governmental initiatives and funding. Major trends projected for the forecast period encompass innovation in diagnostic methods, the advent of targeted therapies, the application of telemedicine and remote monitoring, combination therapies, and progress in lung transplantation.

Get your idiopathic pulmonary fibrosis market report here!

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

What main drivers are fueling expansion in the idiopathic pulmonary fibrosis market?

The idiopathic pulmonary fibrosis market is predicted to grow due to an increase in the incidence of fibrotic diseases. These diseases, otherwise known as fibrosis, are a group of health conditions distinguished by the overstated construction and buildup of connective fibrous tissue in various tissues or organs. Drugs used for idiopathic pulmonary fibrosis help limit lung fibrosis and inflammation by focusing on numerous signaling pathways involved in fibrosis. For example, data from the American Lung Association, a US-based organization, showed that in December 2022 close to 207,000 individuals in the United States were affected and around 58,000 fresh cases of idiopathic pulmonary fibrosis were identified yearly. The disease is often detected in men more than women and frequently influences individuals aged over 50 years. Hence, the growth in the number of fibrotic disease cases propels the idiopathic pulmonary fibrosis market.

What key areas define the segmentation of the global idiopathic pulmonary fibrosis market?

The idiopathic pulmonary fibrosis market covered in this report is segmented –

1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types

2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers

5) By End Users: Hospitals And Clinics, Other End Users

Subsegments:

1) By Nintedanib: Indications, Dosage Forms, Administration Routes

2) By Pirfenidone: Indications, Dosage Forms, Administration Routes

3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12579&type=smp

Who are the dominant players expanding their reach in the idiopathic pulmonary fibrosis market?

Major companies operating in the idiopathic pulmonary fibrosis market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

How are evolving market trends shaping idiopathic pulmonary fibrosis Strategies?

The trend of product innovation is gaining traction within the idiopathic pulmonary fibrosis market. Key players in this market are channeling their efforts towards the development of pioneering products to cement their market standing and obtain a competitive edge. Case in point, Sandoz, a Swiss firm specializing in the production of generic and biosimilar medications, unveiled an AB-rated generic version of pirfenidone in May 2022. This product, the first of its kind to equal Genentech’s Esbriet, is designed to treat patients diagnosed with idiopathic pulmonary fibrosis (IPF). This prescription medicine, which is taken orally, is available through specialty pharmacies. Furthermore, eligible patients stand to gain from a USD 0 co-pay program.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12579

Which regions are emerging as leaders in the idiopathic pulmonary fibrosis market?

North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Overactive Bladder Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/overactive-bladder-treatment-global-market-report

Pulmonary Arterial Hypertension Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: